While reverse vaccinology has accelerated the identification of new antigenic epitopes on infectious agents, tumors and allergens, as well as expanded the development of broadly neutralizing monoclonal antibodies, the current limiting factor is the conversion of these antigenic epitopes into efficient immunogens deliverable as vaccines. VLP Biotech, Inc. has developed a hybrid virus-like-particle (VLP) technology for this purpose. This VLP technology represents a major advancement in medicine because it generates higher levels of therapeutic or prophylactic antibodies compared to other subunit vaccines. Further, the predominant limitations of hybrid-VLP platforms to date have been: (1) instability upon insertion of foreign epitopes and (2) the conformational requirements of nonlinear epitopes. Using our Combinatorial VLP Technology both these obstacles have been overcome. Eliciting stronger immune responses will allow us to achieve successful clinical outcomes with fewer immunizations than required by other subunit vaccines.
Summary of Advantages:
- Bacterial expression allows a cost effective, quick turnaround (a matter of less than a month in most cases)
- Carrier function allows application in multiple diseases (i.e. flu, HBV, Alzheimer's disease, lipid disorders, allergies), representing a significant value for investors
- Owing to the strong immune response elicited by this technology, it has the added potential to replace cumbersome and costly passive monoclonal antibody treatments
- Ability to target indications such as HCV and cancer which should be eligible for orphan drug status, thereby expediting clinical development
Images courtesy of Princeton University & National Center for Biotechnology Information, U.S. National Library of Medicine.
© 2005-2016 VLP Biotech, Inc.